Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
OBJECTIVE: To establish a resistance (R) surveillance program monitoring antimicrobial susceptibility patterns in Latin America (LATAM; Argentina [ARG], Brazil [BRA], Chile, Colombia [CBA], Costa Rica, Ecuador [ECU], Guatemala [GUA], Mexico [MEX], Panama [PAN], Peru, and Venezuela [VEN]). METHODS: I...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600009&lng=en&tlng=en |
id |
doaj-edeb4978bbbb4ade95f1e38f04b2a220 |
---|---|
record_format |
Article |
spelling |
doaj-edeb4978bbbb4ade95f1e38f04b2a2202020-11-25T03:48:10ZengElsevierBrazilian Journal of Infectious Diseases1678-439117667268110.1016/j.bjid.2013.07.002S1413-86702013000600009Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)Ronald N. Jones0Manuel Guzman-Blanco1Ana C. Gales2Belisario Gallegos3Aura Lucia Leal Castro4Marines Dalla Valle Martino5Silvio Vega6Jeannete Zurita7Mario Cepparulo8Mariana Castanheira9JMI LaboratoriesCentro Médico de CaracasUniversidade Federal de São PauloCentro Médico de CaracasHospital El TunalHospital Israelita Albert EinsteinComplejo Hospitalario MetropolitanoHospital Vozandes QuitoPfizer Inc.JMI LaboratoriesOBJECTIVE: To establish a resistance (R) surveillance program monitoring antimicrobial susceptibility patterns in Latin America (LATAM; Argentina [ARG], Brazil [BRA], Chile, Colombia [CBA], Costa Rica, Ecuador [ECU], Guatemala [GUA], Mexico [MEX], Panama [PAN], Peru, and Venezuela [VEN]). METHODS: In 2011, 4979 organisms were collected from 11 nations (20 laboratories) for susceptibility testing in a central laboratory design. Antimicrobials were tested by CLSI methods and results interpreted by CLSI and EUCAST breakpoints. Most common Gram-positive (Staphylococcus aureus [SA, 921], other staphylococci [CoNS; 299], enterococci [218], Streptococcus pneumoniae [SPN; 182], β-haemolytic streptococci [115]) and Gram-negative (E. coli [EC; 644], Klebsiella spp. [KSP; 517], Enterobacters [272], Pseudomonas aeruginosa [PSA; 586], Acinetobacters [ACB; 494]) pathogens were analyzed against linezolid (LZD), vancomycin (VAN), tigecycline (TIG), colistin (COL), cefoperazone/sulbactam (C/S), and amikacin (AMK). RESULTS: MRSA rates varied from 29% (CBA, BRA) to 79% (Peru); but LZD (MIC90, 2 mg/L), TIG (MIC90, 0.12mg/L) and VAN (MIC90, 1mg/L) covered all strains. Enterococci showed a 14% VRE rate, highest in BRA and MEX; all inhibited by TIG and daptomycin, but not LZD (three non-susceptible with G2576T mutations or cfr). Penicillin-R among SPN and viridans streptococci was 51.6 and 41.1%, respectively. LZD overall R against Gram-positives was 0.3%. High ESBL rates were observed in EC (54-71%) and KSP (>50%) from GUA, MEX and Peru, and six nations, respectively. Carbapenem-R in KSP was 9%, highest rates associated with KPC in BRA, CBA, ECU, PAN and VEN; also a NDM-1 in KSP from CBA. AMK, TIG, C/S and carbapenems were the broadest-spectrum agents tested against Enterobacteriaceae. Only COL inhibited >90% of PSA; COL and TIG (<2 mg/L) covered >85% of ACB. CONCLUSIONS: LATAM nations demonstrated variable levels of antimicrobial R especially among Enterobacteriaceae (β-lactamase-mediated), PSA and ACB. MRSA (48%), VRE (14%) and multidrug-R SPN were also regional therapeutic challenges.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600009&lng=en&tlng=enLatin AmericaSurveillanceResistanceESBLβ-Lactamases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ronald N. Jones Manuel Guzman-Blanco Ana C. Gales Belisario Gallegos Aura Lucia Leal Castro Marines Dalla Valle Martino Silvio Vega Jeannete Zurita Mario Cepparulo Mariana Castanheira |
spellingShingle |
Ronald N. Jones Manuel Guzman-Blanco Ana C. Gales Belisario Gallegos Aura Lucia Leal Castro Marines Dalla Valle Martino Silvio Vega Jeannete Zurita Mario Cepparulo Mariana Castanheira Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) Brazilian Journal of Infectious Diseases Latin America Surveillance Resistance ESBL β-Lactamases |
author_facet |
Ronald N. Jones Manuel Guzman-Blanco Ana C. Gales Belisario Gallegos Aura Lucia Leal Castro Marines Dalla Valle Martino Silvio Vega Jeannete Zurita Mario Cepparulo Mariana Castanheira |
author_sort |
Ronald N. Jones |
title |
Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) |
title_short |
Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) |
title_full |
Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) |
title_fullStr |
Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) |
title_full_unstemmed |
Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011) |
title_sort |
susceptibility rates in latin american nations: report from a regional resistance surveillance program (2011) |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1678-4391 |
description |
OBJECTIVE: To establish a resistance (R) surveillance program monitoring antimicrobial susceptibility patterns in Latin America (LATAM; Argentina [ARG], Brazil [BRA], Chile, Colombia [CBA], Costa Rica, Ecuador [ECU], Guatemala [GUA], Mexico [MEX], Panama [PAN], Peru, and Venezuela [VEN]). METHODS: In 2011, 4979 organisms were collected from 11 nations (20 laboratories) for susceptibility testing in a central laboratory design. Antimicrobials were tested by CLSI methods and results interpreted by CLSI and EUCAST breakpoints. Most common Gram-positive (Staphylococcus aureus [SA, 921], other staphylococci [CoNS; 299], enterococci [218], Streptococcus pneumoniae [SPN; 182], β-haemolytic streptococci [115]) and Gram-negative (E. coli [EC; 644], Klebsiella spp. [KSP; 517], Enterobacters [272], Pseudomonas aeruginosa [PSA; 586], Acinetobacters [ACB; 494]) pathogens were analyzed against linezolid (LZD), vancomycin (VAN), tigecycline (TIG), colistin (COL), cefoperazone/sulbactam (C/S), and amikacin (AMK). RESULTS: MRSA rates varied from 29% (CBA, BRA) to 79% (Peru); but LZD (MIC90, 2 mg/L), TIG (MIC90, 0.12mg/L) and VAN (MIC90, 1mg/L) covered all strains. Enterococci showed a 14% VRE rate, highest in BRA and MEX; all inhibited by TIG and daptomycin, but not LZD (three non-susceptible with G2576T mutations or cfr). Penicillin-R among SPN and viridans streptococci was 51.6 and 41.1%, respectively. LZD overall R against Gram-positives was 0.3%. High ESBL rates were observed in EC (54-71%) and KSP (>50%) from GUA, MEX and Peru, and six nations, respectively. Carbapenem-R in KSP was 9%, highest rates associated with KPC in BRA, CBA, ECU, PAN and VEN; also a NDM-1 in KSP from CBA. AMK, TIG, C/S and carbapenems were the broadest-spectrum agents tested against Enterobacteriaceae. Only COL inhibited >90% of PSA; COL and TIG (<2 mg/L) covered >85% of ACB. CONCLUSIONS: LATAM nations demonstrated variable levels of antimicrobial R especially among Enterobacteriaceae (β-lactamase-mediated), PSA and ACB. MRSA (48%), VRE (14%) and multidrug-R SPN were also regional therapeutic challenges. |
topic |
Latin America Surveillance Resistance ESBL β-Lactamases |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600009&lng=en&tlng=en |
work_keys_str_mv |
AT ronaldnjones susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT manuelguzmanblanco susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT anacgales susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT belisariogallegos susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT auralucialealcastro susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT marinesdallavallemartino susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT silviovega susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT jeannetezurita susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT mariocepparulo susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 AT marianacastanheira susceptibilityratesinlatinamericannationsreportfromaregionalresistancesurveillanceprogram2011 |
_version_ |
1724499832375083008 |